Purchase Order 75N93018P01353

Award Date 9/17/18
Potential Completion Date 9/16/19
Potential Value $68K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Austin, TX 78727, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm-fixed price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services (HHS), to Luminex Corporation, a manufacturer of biological testing technologies. The contract is for the delivery of RPP NXTAG (RUO) 96 TESTS, with a potential value of $129,790.00 and a completion date of May 30, 2018. This appears to be a direct award to Luminex, as there is no set-aside designation noted. Luminex has a...
This firm-fixed-price purchase order was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Luminex Corporation for the purchase of an XTAG RVP KIT - IVD. The total ceiling value of the award is $38,400.00. Luminex, a manufacturer of biological testing technologies, provides multiplex diagnostic solutions and related products to various government agencies through prime and subcontract awards. This award is not...
This is a firm fixed-price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to Luminex Corp, a manufacturer of biological testing technologies. The $18,260.00 contract is for the delivery of a respiratory pathogen panel and MagPix drive fluid, which support NIAID's clinical testing programs and biomedical research efforts. Luminex, as a prime contractor, has provided specialized multiplexing systems and...
This is a $22,500.00 firm fixed price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Luminex Corp, a manufacturer of biological testing technologies. The contract is for RPP NXTAG (RUO) 96 TESTS, which are likely multiplex diagnostic assays or reagents used in clinical laboratory and life science research settings. Luminex often serves as a prime contractor providing specialized multiplexing systems and diagnostic products to federal agencies...
This is a federal purchase order for a service agreement worth $32,855.00 awarded to Luminex Corp, a foreign-owned, for-profit manufacturer of biological testing technologies. The contract was awarded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) to provide a complete yearly service plan for an ImageStream MKII instrument. The award was made on a sole source basis under 41 U.S.C. 1901(e)(2) and FAR 13.106-1 as NIAID determined Luminex was...
This is a firm fixed price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Luminex Corporation. The contract, valued at $19,440.00, is for the provision of RVP IVD Mutation Detection Kits, which are used for respiratory virus panel in vitro diagnostic testing. The award did not utilize any set-aside designation. Luminex is a manufacturer of biological testing technologies, including...
This federal contract award to Luminex Corp is for the renewal and maintenance of a Luminex 100 multiplex diagnostic system for the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH). The $5,700 purchase order was awarded on November 18, 2009 with a completion date of December 1, 2010. Luminex, a for-profit manufacturer of biological testing technologies, provides specialized multiplexing platforms, assays, and related services...
This is a firm fixed price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to Luminex Corporation. The $13,690.00 contract is for the delivery of Luminex Kits, which are multiplex diagnostic solutions used in clinical laboratories and life science research settings. The contract has no set-aside designation. Luminex is a manufacturer of biological testing...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Luminex Corporation, a foreign-owned, for-profit manufacturer of biological testing technologies based in Austin, Texas. The contract is for the supply of the NXTAG Respiratory Pathogen Panel (RPP), a multiplex diagnostic product, with a ceiling value of $69,322.50 and a completion date of February 28, 2025. Luminex is the prime contractor and has received previous federal contract awards and grants,...
This is a $36,972.00 firm fixed-price delivery order awarded by the Medical Supply Chain division of the Defense Logistics Agency to Luminex Corporation, a foreign-owned, for-profit manufacturer of diagnostic testing technologies. The contract is for the delivery of NXTAG Respiratory Pathogen Panel (RPP) diagnostic products, which are used for clinical testing, public health surveillance, and biomedical research efforts across various government agencies. Luminex has received several other...

This federal contract award, valued at $67,690.00, was issued by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Luminex Corporation, a foreign-owned, for-profit manufacturer of biological testing technologies. The contract was for the procurement of 15 units of the RPP NXTAG (RUO) 96 Tests, a multiplex assay that can simultaneously detect 22 respiratory pathogens, to be used in NIAID's ongoing clinical challenge studies to characterize the pathogenesis of influenza infection in humans, evaluate immune responses, and assess novel therapeutics and vaccines. The contract was awarded on a sole-source basis under the statutory authority of 41 U.S.C. 253 (c) (1) and FAR 6.302-1, as NIAID determined Luminex was the only responsible source that could satisfy the agency's requirements. No set-aside designation was used.

Generated 6/1/24, 9:29 AM